2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Pramit Khetrapal, MD, discusses the results of evaluating intracorporeal robotic vs open cystectomy in a multicenter, randomized trial in patients with muscle-invasive bladder cancer.
Pramit Khetrapal, MD, academic clinical fellow in Urology, Barts Health NHS Trust, discusses the results of evaluating intracorporeal robotic vs open cystectomy in a multicenter, randomized trial (NCT03049410) in patients with muscle-invasive bladder cancer (MIBC).
This prospective, controlled trial compared the outcomes from minimal access surgery using a robotic platform vs open radical cystectomy in patients with MIBC.
The primary end point of the trial to measure the number of days patients spent out of the hospital in the 90 days following cystectomy, Khetrapal says. The goal was to determine if the use of minimal access surgery could increase the number of days out of the hospital vs traditional cystectomy, Khetrapal adds.
Data from the trial showed the length of stay following cystectomy was 7 days and 8 days for intracorporeal robotic surgery and open radical surgery, respectively, Khetrapal continues. Looking at the full 90-day period, patients who underwent cystectomy with the robotic platform spent 8 total days in the hospital, compared with 10 days for the open platform, Khetrapal explains. This led to an overall combined number of days out of the hospital of 82 days for the robotic platform, vs 80 days for the for the open platform, Khetrapal concludes.